Subscribe

Core intelligence file · ZEAL.DC-01

Zealand Pharma

NASDAQ Copenhagen: ZEAL.DC · Metabolic / Obesity

Clinaptis stanceConstructive
ConvictionMedium
File status
Core intelligence · Editorial review
Updated
Sep 11, 2026
Company thesis
Untested
Research
0 connected notes
Current read

“Zealand has assembled one of the more strategically relevant amylin-centered obesity portfolios, but Clinaptis has not yet completed a decision-grade security view. Petrelintide's standalone differentiation, the Roche combination strategy and the economics retained by Zealand must be underwritten together rather than converting strong mechanism interest into an automatic valuation conclusion.”

The maintained investment case

Petrelintide is the value anchor and the Roche collaboration validates strategic interest in amylin-based obesity treatment. ZUPREME-1 established credible activity with up to 10.7% mean weight loss at week 42 versus 1.7% for placebo and a clean discontinuation profile.

  1. The investment thesis remains deliberately unfinalized: Phase 3 design, diabetic-population evidence, combination utility and retained economics must be connected to valuation before Clinaptis publishes a stance.

Where the market may differ

Mechanism scarcity and partnership validation are not substitutes for product-level underwriting. Petrelintide's standalone efficacy sits below the highest incretin anchors, so durable value depends on whether tolerability and treatment experience earn a distinct role, whether CT-388 adds efficacy without erasing that advantage, and whether enough economics remain with Zealand.

What matters most
  1. 01

    Performance in people with type 2 diabetes through ZUPREME-2.

  2. 02

    Petrelintide's Phase 3 dose, titration, estimand, efficacy and tolerability profile.

  3. 03

    Whether ZUPREME-1's 10.7% mean weight loss and placebo-like discontinuation profile define a durable standalone segment.

  4. 04

    Whether combination with Roche's CT-388 improves efficacy without losing amylin's tolerability proposition.

  5. 05

    Economics retained by Zealand and competition from incretins, other amylins and next-generation regimens.

  6. 06

    A current valuation model and approved directional stance.